Next Article in Journal
Resveratrol Sensitizes Tamoxifen in Antiestrogen-Resistant Breast Cancer Cells with Epithelial-Mesenchymal Transition Features
Next Article in Special Issue
The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients
Previous Article in Journal
Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
Previous Article in Special Issue
Early Lung Cancer Diagnosis by Biosensors

Exploring the Glycosylation of Serum CA125

NIBRT GlycoScience Group, National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Dublin 4, Ireland
The Mass Spectrometry Resource, Conway Institute, University College Dublin, Dublin 4, Ireland
UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
Department of Pathology and Laboratory Medicine, St Vincent's University Hospital, Dublin 4, Ireland
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2013, 14(8), 15636-15654;
Received: 22 April 2013 / Revised: 15 July 2013 / Accepted: 16 July 2013 / Published: 26 July 2013
(This article belongs to the Special Issue Advances in Cancer Diagnosis)
Ovarian cancer is the most lethal gynaecologic cancer affecting women. The most widely used biomarker for ovarian cancer, CA125, lacks sensitivity and specificity. Here, we explored differences in glycosylation of CA125 between serum from patients with ovarian cancer and healthy controls. We found differences between CA125 N-glycans from patient sera compared to controls. These include increases in core-fucosylated bi-antennary monosialylated glycans, as well as decreases in mostly bisecting bi-antennary and non-fucosylated glycans in patients compared to controls. Measurement of the glycosylated state of CA125 may therefore provide a more specific biomarker for patients with ovarian cancer. View Full-Text
Keywords: CA125; N-glycosylation; biomarker; ovarian cancer CA125; N-glycosylation; biomarker; ovarian cancer
Show Figures

Graphical abstract

MDPI and ACS Style

Saldova, R.; Struwe, W.B.; Wynne, K.; Elia, G.; Duffy, M.J.; Rudd, P.M. Exploring the Glycosylation of Serum CA125. Int. J. Mol. Sci. 2013, 14, 15636-15654.

AMA Style

Saldova R, Struwe WB, Wynne K, Elia G, Duffy MJ, Rudd PM. Exploring the Glycosylation of Serum CA125. International Journal of Molecular Sciences. 2013; 14(8):15636-15654.

Chicago/Turabian Style

Saldova, Radka, Weston B. Struwe, Kieran Wynne, Giuliano Elia, Michael J. Duffy, and Pauline M. Rudd 2013. "Exploring the Glycosylation of Serum CA125" International Journal of Molecular Sciences 14, no. 8: 15636-15654.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop